Skip to main content
Top
Published in: Annals of Surgical Oncology 13/2022

17-08-2022 | Pancreatectomy | Pancreatic Tumors

Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver

Authors: Isabella Frigerio, MD, PhD, Giuseppe Malleo, MD, PhD, Matteo de Pastena, MD, PhD, Giacomo Deiro, MD, Niccolò Surci, MD, Filippo Scopelliti, MD, Alessandro Esposito, MD, Paolo Regi, MD, Alessandro Giardino, MD, PhD, Valentina Allegrini, MD, Claudio Bassi, MD, Roberto Girelli, MD, Roberto Salvia, MD, PhD, Giovanni Butturini, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Abstract

Background

Resection of initially oligometastatic pancreatic ductal adenocarcinoma (PDAC) following response to first-line chemotherapy is controversial. We herein updated a previous case series to investigate the oncologic outcomes and preoperative factors that could drive the decision-making process.

Methods

This retrospective analysis was limited to patients with liver-only synchronous metastases who experienced complete regression of the metastatic component and underwent pancreatectomy between October 2008 and July 2020 at two high-volume institutions. Clinical-pathologic variables were captured, and inflammation-based prognostic scores were calculated. Recurrence and survival analyses were performed using standard statistical methods.

Results

Overall, 52 patients were included. FOLFIRINOX was the most employed chemotherapy regimen (63.5%). Post-treatment tumor size, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) were significantly decreased relative to baseline evaluation. The median time from diagnosis to pancreatectomy was 10.2 months, while the median time from chemotherapy completion to pancreatectomy was 2 months. Major postoperative complications occurred in 26.9% of patients, while postoperative mortality was nil. The median disease-free survival (DFS) and overall survival (OS) from pancreatectomy were 16.5 and 23.0 months, respectively, and the median OS from diagnosis was 37.2 months. At multivariable analysis, vascular resection, operative time, prognostic nutrition index (PNI) and neutrophil-to-lymphocyte ratio (NLR) were associated with OS. Operative time, platelet × neutrophil/lymphocyte count (SII), and PNI were associated with DFS.

Conclusions

We confirm promising outcomes of selected patients who underwent pancreatectomy following downstaging of liver metastases. The absence of vascular involvement of the primary tumor, good nutritional status, and low inflammatory index scores could be useful to select candidates for resection.
Literature
1.
3.
go back to reference Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2006;14:118–27.CrossRefPubMed Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2006;14:118–27.CrossRefPubMed
4.
go back to reference Antoniou E, Margonis GA, Sasaki K, et al. Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature. ANZ J Surg. 2016;86:973–7.CrossRefPubMed Antoniou E, Margonis GA, Sasaki K, et al. Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature. ANZ J Surg. 2016;86:973–7.CrossRefPubMed
5.
go back to reference Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? World J Surg Oncol. 2014;12:347.CrossRefPubMedPubMedCentral Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? World J Surg Oncol. 2014;12:347.CrossRefPubMedPubMedCentral
6.
go back to reference Tachezy M, Gebauer F, Janot M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160:136–44.CrossRefPubMed Tachezy M, Gebauer F, Janot M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160:136–44.CrossRefPubMed
7.
go back to reference Hackert T, Niesen W, Hinz U, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43:358–63.CrossRefPubMed Hackert T, Niesen W, Hinz U, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43:358–63.CrossRefPubMed
8.
go back to reference Tao L, Yuan C, Ma Z, Jiang B, Xiu D. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manag Res. 2017;9:471–9.CrossRefPubMedPubMedCentral Tao L, Yuan C, Ma Z, Jiang B, Xiu D. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manag Res. 2017;9:471–9.CrossRefPubMedPubMedCentral
9.
go back to reference Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a surveillance epidemiology and end results database analysis. World J Gastroenterol. 2017;23:1872–80.CrossRefPubMedPubMedCentral Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a surveillance epidemiology and end results database analysis. World J Gastroenterol. 2017;23:1872–80.CrossRefPubMedPubMedCentral
10.
11.
go back to reference Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed
12.
go back to reference Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef
13.
go back to reference Kandel P, Wallace MB, Stauffer J, et al. Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study. J Pancreat Cancer. 2018;4:88–94.CrossRefPubMedPubMedCentral Kandel P, Wallace MB, Stauffer J, et al. Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study. J Pancreat Cancer. 2018;4:88–94.CrossRefPubMedPubMedCentral
14.
go back to reference Crippa S, Bittoni A, Sebastiani E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42:1533–9.CrossRefPubMed Crippa S, Bittoni A, Sebastiani E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42:1533–9.CrossRefPubMed
15.
go back to reference Byun Y, Han Y, Kang JS, et al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J Hepato-Biliary-Pancreat Sci. 2019;26:416–25.CrossRef Byun Y, Han Y, Kang JS, et al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J Hepato-Biliary-Pancreat Sci. 2019;26:416–25.CrossRef
16.
go back to reference Tanaka M, Heckler M, Mihaljevic AL, et al. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol. 2019;45:1453–9.CrossRefPubMed Tanaka M, Heckler M, Mihaljevic AL, et al. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol. 2019;45:1453–9.CrossRefPubMed
17.
go back to reference Wright GP, Poruk KE, Zenati MS, et al. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J Gastrointest Surg. 2016;20:1830–5.CrossRefPubMed Wright GP, Poruk KE, Zenati MS, et al. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J Gastrointest Surg. 2016;20:1830–5.CrossRefPubMed
18.
go back to reference Nie D, Lai G, An G, et al. Individualized prediction of survival benefits of pancreatectomy plus chemotherapy in patients with simultaneous metastatic pancreatic cancer. Front Oncol. 2021;11:719253.CrossRefPubMedPubMedCentral Nie D, Lai G, An G, et al. Individualized prediction of survival benefits of pancreatectomy plus chemotherapy in patients with simultaneous metastatic pancreatic cancer. Front Oncol. 2021;11:719253.CrossRefPubMedPubMedCentral
19.
go back to reference Frigerio I, Regi P, Giardino A, et al. Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol. 2017;24:2397–403.CrossRefPubMed Frigerio I, Regi P, Giardino A, et al. Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol. 2017;24:2397–403.CrossRefPubMed
20.
go back to reference Crippa S, Cirocchi R, Weiss MJ, et al. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg. 2020;72:39–45.CrossRefPubMed Crippa S, Cirocchi R, Weiss MJ, et al. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg. 2020;72:39–45.CrossRefPubMed
21.
go back to reference De Simoni O, Scarpa M, Tonello M, et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: Which role for conversion surgery? A systematic review and meta-analysis. Cancers. 2020;12:3402.CrossRefPubMedCentral De Simoni O, Scarpa M, Tonello M, et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: Which role for conversion surgery? A systematic review and meta-analysis. Cancers. 2020;12:3402.CrossRefPubMedCentral
22.
go back to reference Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161:584–91.CrossRefPubMed Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161:584–91.CrossRefPubMed
23.
go back to reference Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH)–an international study group of pancreatic surgery (ISGPS) definition. Surgery. 2007;142:20–5.CrossRefPubMed Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH)–an international study group of pancreatic surgery (ISGPS) definition. Surgery. 2007;142:20–5.CrossRefPubMed
24.
go back to reference Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761–8.CrossRefPubMed Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761–8.CrossRefPubMed
25.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral
26.
go back to reference Jabłońska B, Pawlicki K, Mrowiec S. Associations between nutritional and immune status and clinicopathologic factors in patients with pancreatic cancer: a comprehensive analysis. Cancers. 2021;13:5041.CrossRefPubMedPubMedCentral Jabłońska B, Pawlicki K, Mrowiec S. Associations between nutritional and immune status and clinicopathologic factors in patients with pancreatic cancer: a comprehensive analysis. Cancers. 2021;13:5041.CrossRefPubMedPubMedCentral
27.
go back to reference Edge SB, Byrd DR, Compton CC, et al editors. AJCC Cancer Staging Manual. 7th edn. New York: Springer; 2010. Edge SB, Byrd DR, Compton CC, et al editors. AJCC Cancer Staging Manual. 7th edn. New York: Springer; 2010.
28.
go back to reference Pausch TM, Liu X, Cui J, et al. Survival benefit of resection surgery for pancreatic ductal adenocarcinoma with liver metastases: a propensity score-MAtched SEER database analysis. Cancers. 2021;14:57.CrossRefPubMedPubMedCentral Pausch TM, Liu X, Cui J, et al. Survival benefit of resection surgery for pancreatic ductal adenocarcinoma with liver metastases: a propensity score-MAtched SEER database analysis. Cancers. 2021;14:57.CrossRefPubMedPubMedCentral
29.
go back to reference Tsai S, George B, Wittmann D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg. 2020;271:740–7.CrossRefPubMed Tsai S, George B, Wittmann D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg. 2020;271:740–7.CrossRefPubMed
30.
go back to reference Reni M, Zanon S, Balzano G, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017;28:2786–92.CrossRefPubMed Reni M, Zanon S, Balzano G, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017;28:2786–92.CrossRefPubMed
31.
go back to reference Maggino L, Malleo G, Marchegiani G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154:932–42.CrossRefPubMedPubMedCentral Maggino L, Malleo G, Marchegiani G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154:932–42.CrossRefPubMedPubMedCentral
32.
go back to reference Kleive D, Sahakyan MA, Berstad AE, et al. Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. Br J Surg. 2017;104:1558–67.CrossRefPubMed Kleive D, Sahakyan MA, Berstad AE, et al. Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. Br J Surg. 2017;104:1558–67.CrossRefPubMed
33.
go back to reference Belfiori G, Fiorentini G, Tamburrino D, et al. Vascular resection during pancreatectomy for pancreatic head cancer: a technical issue or a prognostic sign? Surgery. 2021;169:403–10.CrossRefPubMed Belfiori G, Fiorentini G, Tamburrino D, et al. Vascular resection during pancreatectomy for pancreatic head cancer: a technical issue or a prognostic sign? Surgery. 2021;169:403–10.CrossRefPubMed
34.
go back to reference Nakagawa K, Sho M, Akahori T, et al. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Pancreatology. 2019;19:722–8.CrossRefPubMed Nakagawa K, Sho M, Akahori T, et al. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Pancreatology. 2019;19:722–8.CrossRefPubMed
35.
go back to reference Ahmad J, Grimes N, Farid S, Morris-Stiff G. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2014;13:474–81.CrossRefPubMed Ahmad J, Grimes N, Farid S, Morris-Stiff G. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2014;13:474–81.CrossRefPubMed
36.
go back to reference Perlmutter BC, Ali J, Turgut BC, et al. Correlation between physical status measures and frailty score in patients undergoing pancreatic resection. Surgery. 2022;171:711–7.CrossRefPubMed Perlmutter BC, Ali J, Turgut BC, et al. Correlation between physical status measures and frailty score in patients undergoing pancreatic resection. Surgery. 2022;171:711–7.CrossRefPubMed
Metadata
Title
Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
Authors
Isabella Frigerio, MD, PhD
Giuseppe Malleo, MD, PhD
Matteo de Pastena, MD, PhD
Giacomo Deiro, MD
Niccolò Surci, MD
Filippo Scopelliti, MD
Alessandro Esposito, MD
Paolo Regi, MD
Alessandro Giardino, MD, PhD
Valentina Allegrini, MD
Claudio Bassi, MD
Roberto Girelli, MD
Roberto Salvia, MD, PhD
Giovanni Butturini, MD, PhD
Publication date
17-08-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12385-4

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue